Subjects of human abuse potential (HAP) studies must be able to detect liking with the investigational drug. However, many subjects recruited for HAP studies use marijuana, and THC is often exempt from exclusion by urine drug tests (UDTs). PRA Health Sciences examined whether UDT evidence of recent marijuana use was associated with a difference in subjects’ ability to discriminate opioid from placebo. Successful opioid discriminators were associated with a statistically insignificant, but higher positive THC UDT rate and mean carboxy-THC urine concentration when compared to non-discriminators, indicating that recent users of marijuana may not need to be excluded from opioid HAP studies.
Sleep Hygiene, “Coronasomnia,” and Future Treatments
Read on to learn why regular sleep is so important and how the biopharma industry is addressing gaps in available insomnia therapies.
Alzheimer's Disease Research 2018
PRA conducted a survey at the 2018 Alzheimer's Association International Conference in Chicago. Across the board we found that the research community…
Ask the Experts: What Do We Need to Know About ALZ and other Brain-Related Illnesses?
Many people have heard of brain-related illnesses such as Alzheimer’s (ALZ). In honor of Brain Awareness Month, we shed some light on ALZ and other…